Tan Xiangyun, Huang Xinyu, Lu Zhuhang, Chen Liang, Hu Junjie, Tian Xianxiang, Qiu Zhenpeng
College of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Hubei Key Laboratory of Resources and Chemistry of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China.
Front Pharmacol. 2023 Mar 8;14:1124003. doi: 10.3389/fphar.2023.1124003. eCollection 2023.
Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disease with increasing prevalence. Lipophagy is a type of programmed cell death that plays an essential role in maintaining the body's balance of fatty acid metabolism. However, the livers of NAFLD patients are abnormally dysregulated in lipophagy. mTORC1 is a critical negative regulator of lipophagy, which has been confirmed to participate in the process of lipophagy through various complex mechanisms. Therefore, targeting mTORC1 to restore failed autophagy may be an effective therapeutic strategy for NAFLD. This article reviews the main pathways through which mTORC1 participates in the formation of lipophagy and the intervention effect of mTORC1-regulated lipophagy in NAFLD, providing new therapeutic strategies for the prevention and treatment of NAFLD in the future.
非酒精性脂肪性肝病(NAFLD)是一种患病率不断上升的慢性进行性肝病。脂质自噬是一种程序性细胞死亡类型,在维持机体脂肪酸代谢平衡中发挥着重要作用。然而,NAFLD患者的肝脏在脂质自噬方面存在异常失调。mTORC1是脂质自噬的关键负调控因子,已证实其通过多种复杂机制参与脂质自噬过程。因此,靶向mTORC1以恢复失败的自噬可能是NAFLD的一种有效治疗策略。本文综述了mTORC1参与脂质自噬形成的主要途径以及mTORC1调节的脂质自噬在NAFLD中的干预作用,为未来NAFLD的防治提供新的治疗策略。